title: Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study.
abstract: L-[3-(18)F]-alpha-methyltyrosine ((18)F-FMT) is an aminoacid tracer for positron emission tomography (PET). The aim of this study was to determine whether PET-CT with (18)F-FMT provides additional information for the preoperative diagnostic workup as compared with (18)F-FDG PET. PET-CT studies with (18)F-FMT and (18)F-FDG were performed as a part of the preoperative workup in 36 patients with histologically confirmed bronchial carcinoma, 6 patients with benign lesions and a patient with atypical carcinoid. Expression of L-type amino acid transporter 1 (LAT1), CD98, Ki-67 labeling index, VEGF, CD31 and CD34 of the resected tumors were analyzed by immunohistochemical staining, and correlated with the uptake of PET tracers. For the detection of pulmonary malignant tumors, (18)F-FMT PET exhibited a sensitivity of 84% whereas the sensitivity for (18)F-FDG PET was 89% (p = 0.736). (18)F-FMT PET-CT and (18)F-FDG PET-CT agreed with pathological staging in 85 and 68%, respectively (p = 0.151). (18)F-FMT uptake was closely correlated with LAT1, CD98, cell proliferation and angiogenesis. The specificity of (18)F-FMT PET for diagnosing thoracic tumors was higher than that of (18)F-FDG PET. Our results suggest that coexpression of LAT1 and CD98 in addition to cell proliferation and angiogenesis is relavant for the progression and metastasis of lung cancer.
authors.affiliation: Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. kkaira1970@yahoo.co.jp
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.forename: Noboru
authors.initials: N
authors.lastname: Oriuchi
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Shimizu
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ishikita
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Higuchi
authors.forename: Hisao
authors.initials: H
authors.lastname: Imai
authors.forename: Noriko
authors.initials: N
authors.lastname: Yanagitani
authors.forename: Noriaki
authors.initials: N
authors.lastname: Sunaga
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hisada
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Ishizuka
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Kanai
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Endou
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Keigo
authors.initials: K
authors.lastname: Endo
authors.forename: Masatomo
authors.initials: M
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D005260:Female; D019788:Fluorodeoxyglucose F18; D027261:Fusion Regulatory Protein-1 / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D027283:Large Neutral Amino Acid-Transporter 1 / Q000032:analysis; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D013899:Thoracic Neoplasms / Q000473:pathology*; D014057:Tomography, X-Ray Computed; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis; D019805:alpha-Methyltyrosine
chemical_list: D018952:Antigens, CD34; D027261:Fusion Regulatory Protein-1; D027283:Large Neutral Amino Acid-Transporter 1; D019275:Radiopharmaceuticals; D042461:Vascular Endothelial Growth Factor A; D019788:Fluorodeoxyglucose F18; D019805:alpha-Methyltyrosine